Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

INT2ACT Innovative Nucleic Acids Technologies for Analysis, Detection and Treatment

Coordinator
Universita Degli Studi Di Udine, Italy
Runs
1 January 2026 to 31 December 2029
Status
Running
EU funding
€4.5m
Total cost
—
Partners
28 organisations in 11 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101226670

What the project is doing

In the project's own words, from its summary on CORDIS.

In recent years, nucleic acids (NAs) have contributed significantly to advancing the diagnosis and treatment of diseases such as cancer, infectious and rare diseases. Breakthrough technologies like genome editing tool CRISPR/Cas9, direct RNA sequencing, multi-omics analysis procedure for NAs analysis, bioinformatics and machine learning for data analysis, and targeted delivery systems based on lipid nanoparticles (LNPs) prove the increasing interest in NAs applicability.

However, the full potential of NAs is yet to be unlocked, and the translation of NAs into clinical practice is still facing many methodological and technological limitations such as low detection sensitivity, limited sequencing capacity, lack of analytical methods for NAs therapeutics, and inadequate in vivo delivery. INT2ACT brings together 6 academic research units and 5 industrial partners to address these limitations by establishing new methods for detecting and analysing NAs in patient liquid biopsies, boosting available procedures for direct RNA sequencing, developing new methods for the synthesis and analysis of antisense oligonucleotides (ASO) libraries, identifying new RNA targets, and optimise NA therapeutics delivery systems.

The concept of harnessing NAs in the realm of medicine opens doors to an array of possibilities, including the development of therapeutic vaccines for cancer and innovative ASO-based therapies for addressing a multitude of genetic disorders. While advancing NAs’ research and technologies, INT2ACT will also contribute to forming the next generation of highly skilled experts through an interdisciplinary and intersectoral training programme delivered to 15 Doctoral Candidates.

The network-wide training programme is designed to ensure that all INT2ACT fellows will have the skills for a successful career in or outside of research in any sector.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di UdineUdineItalyCoordinator
Accelopment Schweiz AGZurichSwitzerlandAssociatedpartner
Shanghai UniversityShanghaiChinaAssociatedpartner
Baseclick GmbHNeuriedGermanyParticipant
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyAssociatedpartner
Asociacion Instituto De Investigacion Sanitaria BiogipuzkoaDonostia-San SebastianSpainParticipant
Flomics Biotech SLBarcelonaSpainParticipant
Fundacio Universitat Pompeu Fabra(barcelona)BarcelonaSpainAssociatedpartner
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainAssociatedpartner
National Institute for Bioprocessing Research and Training LimitedBlackrock DublinIrelandParticipant
University College Dublin, National University of Ireland, DublinDublinIrelandParticipant
Mana Bio LtdTel AvivIsraelAssociatedpartner
Technion - Israel Institute of TechnologyHaifaIsraelAssociatedpartner
Technion Research and Development Foundation LtdHaifaIsraelParticipant
Center for Ethics in Science and Science Journalism - Centro per L'etica Nella Scienza E Nel Giornalismo ScientificoMilanoItalyAssociatedpartner
Fondazione Istituto Italiano Di TecnologiaGenovaItalyParticipant
Istituto Nazionale Di Biostrutture E BiosistemiRomaItalyAssociatedpartner
Istituto Universitario Di Studi Superiori ( I.u.s.s.) Di PaviaPaviaItalyAssociatedpartner
Instytut Chemii Bioorganicznej Polskiej Akademii NaukPoznanPolandParticipant
Oneki ABStockholmSwedenAssociatedpartner
Astrazeneca UK LimitedCambridgeUnited KingdomAssociatedpartner
Careers Research and Advisory Centre (crac) Limited (the)CambridgeUnited KingdomAssociatedpartner
Nanovery LtdNewcastle Upon TyneUnited KingdomAssociatedpartner
Nanovery LtdNewcastle Upon TyneUnited KingdomParticipant
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomAssociatedpartner
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomParticipant
University of SouthamptonSouthamptonUnited KingdomParticipant
Johns Hopkins UniversityBaltimoreUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS